<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897452</url>
  </required_header>
  <id_info>
    <org_study_id>EU-Grant 223767</org_study_id>
    <secondary_id>2011-000310-19</secondary_id>
    <nct_id>NCT03897452</nct_id>
  </id_info>
  <brief_title>NeoFent-I Study; Fentanyl Treatment in Newborn Infants; a Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study</brief_title>
  <official_title>NeoFent-I Study; Fentanyl Treatment in Newborn Infants; a Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study. Prestudy to NeoOpioid; No Pain During Infancy by Adapting Off-patent Medicines. EU FP7:HEALTH - 2007-4.2-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the efficacy of fentanyl using a pharmacokinetic/pharmacodynamic
      (PK/PD) model where the concentration of the drug is related to effect curve (pain score
      change in response to standardized procedural pain). Further cortical, physiological and
      biochemical responses to fentanyl will be assessed, elucidating the feasibility before the
      main study project (NeoOpioid) start.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">December 31, 2014</completion_date>
  <primary_completion_date type="Actual">December 31, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics; fentanyl clearance</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration will be analysed and the clearance will be calculated with NONMEM pharmacokinetics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics; fentanyl clearance</measure>
    <time_frame>6 hours</time_frame>
    <description>The serum concentration values will be analysed as Area under the curve, AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics; Amplitude integrated electroencephalography (aEEG)</measure>
    <time_frame>6 hours</time_frame>
    <description>Background activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics; Amplitude integrated electroencephalography (aEEG),</measure>
    <time_frame>6 hours</time_frame>
    <description>Seizure activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics, change in vital parameters</measure>
    <time_frame>6 hours</time_frame>
    <description>Change in heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics, change in vital parameters</measure>
    <time_frame>6 hours</time_frame>
    <description>Change in mean arterial blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics, change in vital parameters</measure>
    <time_frame>6 hours</time_frame>
    <description>Change in near infrared spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics, behavioural response</measure>
    <time_frame>6 hours</time_frame>
    <description>Pain assessment with the Premature Infant Pain Profile-revised (PIPP) score for procedural pain (0-21, with the highest value if strong pain in extremely preterm infants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics, hormonal response</measure>
    <time_frame>48 hours</time_frame>
    <description>Blood levels of cortisol</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Fentanyl for procedural pain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of Fentanyl 5 microgram/ml, 0.5 microgram/kg (anticipated medium pain) or 2 microgram/kg (anticipated strong pain) will be given prior to a painful procedure during NICU-care. Repeated doses or complementary analgesics will be administered according to pain assessment and clinical judgement.
This is not an RCT with several arms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl (5 microgram/ml) prediluted ampoules</intervention_name>
    <description>Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.
Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation).</description>
    <arm_group_label>Fentanyl for procedural pain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical indication for analgesia before any of following procedures;

               1. insertion of peripheral IV-catheter

               2. insertion of arterial cannula

               3. insertion of chest tube

               4. other skin breaking procedure.

          -  Possibility to obtain blood samle after the procedure (indwelling line)

          -  Infants all gestational ages.

          -  Postnatal age 0-28 days

          -  Informed written parental concent

        Exclusion Criteria:

          -  Concurrent or previous opioid administration (72 h interval required)

          -  Abdominal surgery

          -  Major chromosomal anomaly

          -  Neonatal encephalopathy

          -  Use of muscle relaxant

          -  Hypothermia treatment after hypoxic-ischemic insult

          -  Clinical or biochemical evidence of hepatic failure

          -  Participation in other intervention trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vineta Fellman, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Pediatrics, Lund University, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit, Sk√•ne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Elisabeth Norman</investigator_full_name>
    <investigator_title>MD, PhD, Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>analgesia</keyword>
  <keyword>neonates</keyword>
  <keyword>procedural pain</keyword>
  <keyword>pain assessment</keyword>
  <keyword>physiological response</keyword>
  <keyword>pharmacogenetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

